|
1
|
Mohammed A, Janakiram NB, Brewer M,
Ritchie RL, Marya A, Lightfoot S, Steele VE and Rao CV:
Antidiabetic drug metformin prevents progression of pancreatic
cancer by targeting in part cancer stem cells and mTOR signaling.
Transl Oncol. 6:649–659. 2013. View Article : Google Scholar
|
|
2
|
Olive KP, Jacobetz MA, Davidson CJ,
Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA,
Caldwell ME, Allard D, et al: Inhibition of Hedgehog signaling
enhances delivery of chemotherapy in a mouse model of pancreatic
cancer. Science. 324:1457–1461. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tetreault MP, Yang Y and Katz JP:
Krüppel-like factors in cancer. Nat Rev Cancer. 13:701–713. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wei D, Wang L, Kanai M, Jia Z, Le X, Li Q,
Wang H and Xie K: KLF4α up-regulation promotes cell cycle
progression and reduces survival time of patients with pancreatic
cancer. Gastroenterology. 139:2135–2145. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yan Y, Li Z, Kong X, Jia Z, Zuo X, Gagea
M, Huang S, Wei D and Xie K: KLF4-Mediated suppression of CD44
signaling negatively impacts pancreatic cancer stemness and
metastasis. Cancer Res. 76:2419–2431. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rowland BD, Bernards R and Peeper DS: The
KLF4 tumour suppressor is a transcriptional repressor of p53 that
acts as a context-dependent oncogene. Nat Cell Biol. 7:1074–1082.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Meidhof S, Brabletz S, Lehmann W, Preca
BT, Mock K, Ruh M, Schüler J, Berthold M, Weber A, Burk U, et al:
ZEB1-associated drug resistance in cancer cells is reversed by the
class I HDAC inhibitor mocetinostat. EMBO Mol Med. 7:831–847. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Truesdell P, Ahn J, Chander H, Meens J,
Watt K, Yang X and Craig AW: CIP4 promotes lung adenocarcinoma
metastasis and is associated with poor prognosis. Oncogene.
34:3527–3535. 2015. View Article : Google Scholar
|
|
9
|
Xiong H, Hong J, Du W, Lin YW, Ren LL,
Wang YC, Su WY, Wang JL, Cui Y, Wang ZH, et al: Roles of STAT3 and
ZEB1 proteins in E-cadherin down-regulation and human colorectal
cancer epithelial-mesenchymal transition. J Biol Chem.
287:5819–5832. 2012. View Article : Google Scholar :
|
|
10
|
Rhodes LV, Tate CR, Segar HC, Burks HE,
Phamduy TB, Hoang V, Elliott S, Gilliam D, Pounder FN, Anbalagan M,
et al: Suppression of triple-negative breast cancer metastasis by
pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT
master regulators. Breast Cancer Res Treat. 145:593–604. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ma J, Fu G, Wu J, Han S, Zhang L, Yang M,
Yu Y, Zhang M, Lin Y and Wang Y: 4-cholesten-3-one suppresses lung
adeno-carcinoma metastasis by regulating translocation of HMGB1,
HIF1α and Caveolin-1. Cell Death Dis. 7:e23722016. View Article : Google Scholar
|
|
12
|
Xian G, Zhao J, Qin C, Zhang Z, Lin Y and
Su Z: Simvastatin attenuates macrophage-mediated gemcitabine
resistance of pancreatic ductal adenocarcinoma by regulating the
TGF-β1/Gfi-1 axis. Cancer Lett. 385:65–74. 2017. View Article : Google Scholar
|
|
13
|
Wang Z, Li Y, Kong D, Banerjee S, Ahmad A,
Azmi AS, Ali S, Abbruzzese JL, Gallick GE and Sarkar FH:
Acquisition of epithelial-mesenchymal transition phenotype of
gemcitabine-resistant pancreatic cancer cells is linked with
activation of the notch signaling pathway. Cancer Res.
69:2400–2407. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yu T, Chen X, Lin T, Liu J, Li M, Zhang W,
Xu X, Zhao W, Liu M, Napier DL, et al: KLF4 deletion alters gastric
cell lineage and induces MUC2 expression. Cell Death Dis.
7:e22552016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shi M, Cui J, Du J, Wei D, Jia Z, Zhang J,
Zhu Z, Gao Y and Xie K: A novel KLF4/LDHA signaling pathway
regulates aerobic glycolysis in and progression of pancreatic
cancer. Clin Cancer Res. 20:4370–4380. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li H, Wang J, Xiao W, Xia D, Lang B, Yu G,
Guo X, Guan W, Wang Z, Hu Z, et al: Epigenetic alterations of
Krüppel-like factor 4 and its tumor suppressor function in renal
cell carcinoma. Carcinogenesis. 34:2262–2270. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wei D, Wang L, Yan Y, Jia Z, Gagea M, Li
Z, Zuo X, Kong X, Huang S and Xie K: KLF4 is essential for
induction of cellular identity change and acinar-to-ductal
reprogramming during early pancreatic carcinogenesis. Cancer Cell.
29:324–338. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Funel N, Morelli M, Giovannetti E, Del
Chiaro M, Pollina LE, Mosca F, Boggi U, Cavazzana A and Campani D:
Loss of heterozygosity status of D9S105 marker is associated with
downregulation of Kruppel-like factor 4 expression in pancreatic
ductal adenocarcinoma and pancreatic intraepithelial lesions.
Pancreatology. 11:30–42. 2011. View Article : Google Scholar
|
|
19
|
Li Y, VandenBoom TG II, Kong D, Wang Z,
Ali S, Philip PA and Sarkar FH: Up-regulation of miR-200 and let-7
by natural agents leads to the reversal of
epithelial-to-mesenchymal transition in gemcitabine-resistant
pancreatic cancer cells. Cancer Res. 69:6704–6712. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wellner U, Schubert J, Burk UC,
Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D,
zur Hausen A, et al: The EMT-activator ZEB1 promotes tumorigenicity
by repressing stemness-inhibiting microRNAs. Nat Cell Biol.
11:1487–1495. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xia H, Cheung WK, Sze J, Lu G, Jiang S,
Yao H, Bian XW, Poon WS, Kung HF and Lin MC: miR-200a regulates
epithelial-mesenchymal to stem-like transition via ZEB2 and
beta-catenin signaling. J Biol Chem. 285:36995–37004. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen C, Xiang H, Peng YL, Peng J and Jiang
SW: Mature miR-183, negatively regulated by transcription factor
GATA3, promotes 3T3-L1 adipogenesis through inhibition of the
canonical Wnt/β-catenin signaling pathway by targeting LRP6. Cell
Signal. 26:1155–1165. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li Q, Song W, Wang W, Yao S, Tian C, Cai X
and Wang L: Suppression of epithelial-mesenchymal transition in
hepatocellular carcinoma cells by Krüppel-like factor 4.
Oncotarget. 7:29749–29760. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li Y, Zeng C, Tu M, Jiang W, Dai Z, Hu Y,
Deng Z and Xiao W: MicroRNA-200b acts as a tumor suppressor in
osteosarcoma via targeting ZEB1. Onco Targets Ther. 9:3101–3111.
2016.PubMed/NCBI
|
|
25
|
Nishijima N, Seike M, Soeno C, Chiba M,
Miyanaga A, Noro R, Sugano T, Matsumoto M, Kubota K and Gemma A:
miR-200/ZEB axis regulates sensitivity to nintedanib in non-small
cell lung cancer cells. Int J Oncol. 48:937–944. 2016.PubMed/NCBI
|
|
26
|
Yang Y, Ahn YH, Chen Y, Tan X, Guo L,
Gibbons DL, Ungewiss C, Peng DH, Liu X, Lin SH, et al: ZEB1
sensitizes lung adenocarcinoma to metastasis suppression by PI3K
antagonism. J Clin Invest. 124:2696–2708. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kundu ST, Byers LA, Peng DH, Roybal JD,
Diao L, Wang J, Tong P, Creighton CJ and Gibbons DL: The miR-200
family and the miR-183~96~182 cluster target Foxf2 to inhibit
invasion and metastasis in lung cancers. Oncogene. 35:173–186.
2016. View Article : Google Scholar
|
|
28
|
Lehmann W, Mossmann D, Kleemann J, Mock K,
Meisinger C, Brummer T, Herr R, Brabletz S, Stemmler MP and
Brabletz T: ZEB1 turns into a transcriptional activator by
interacting with YAP1 in aggressive cancer types. Nat Commun.
7:104982016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Galván JA, Zlobec I, Wartenberg M, Lugli
A, Gloor B, Perren A and Karamitopoulou E: Expression of E-cadherin
repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells
influences tumour-budding phenotype and suggests heterogeneity of
stromal cells in pancreatic cancer. Br J Cancer. 112:1944–1950.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zheng X, Carstens JL, Kim J, Scheible M,
Kaye J, Sugimoto H, Wu CC, LeBleu VS and Kalluri R:
Epithelial-to-mesenchymal transition is dispensable for metastasis
but induces chemoresistance in pancreatic cancer. Nature.
527:525–530. 2015. View Article : Google Scholar : PubMed/NCBI
|
